GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference
Topics/Oncology/FIT versus colonoscopy in Korea’s national colorectal cancer screening program
153

FIT versus colonoscopy in Korea’s national colorectal cancer screening program

Clinical knowledge base written and curated by GastroAGI Team from primary medical literatureLast updated March 1, 2025

In South Korea's national colorectal cancer (CRC) screening program, the fecal immunochemical test (FIT) and colonoscopy are two key approaches, each with distinct advantages and limitations. Here's a detailed comparison of FIT versus colonoscopy in the context of Korea's CRC screening program:

Fecal Immunochemical Test (FIT)

Advantages:

  1. Simplicity and Noninvasiveness:
  • FIT is a stool-based test that detects hidden blood in feces, which may indicate the presence of colorectal cancer or advanced adenomas.
  • It is noninvasive, making it more acceptable to the general population compared to colonoscopy.
  1. Cost-Effectiveness:
  • FIT is relatively inexpensive, which makes it suitable for large-scale implementation as part of a national screening program.
  1. Ease of Administration:
  • The test is easy to perform at home and does not require specialized equipment or trained medical personnel for the initial sample collection.
  1. High Participation Rates:
  • Its simplicity and affordability encourage broader public participation, which is critical for the success of mass screening programs.

Limitations:

  1. Lower Diagnostic Accuracy:
  • FIT has limited sensitivity for detecting advanced adenomas or early-stage colorectal cancer. It is more effective at identifying cancers that are already bleeding but may miss precancerous lesions.
  1. Reliance on Consistent Participation:
  • FIT needs to be performed annually or biennially to maintain effectiveness, requiring consistent public adherence to the screening schedule.
  1. No Therapeutic Capability:
  • FIT is purely a diagnostic tool. If the test result is positive, a follow-up colonoscopy is required to confirm the diagnosis and remove any precancerous lesions.

Colonoscopy

Advantages:

  1. High Diagnostic Accuracy:
  • Colonoscopy allows direct visualization of the entire colon and rectum, making it highly accurate for detecting colorectal cancer and advanced adenomas.
  1. Dual Diagnostic and Therapeutic Capability:
  • During the same procedure, precancerous lesions (e.g., adenomas or polyps) can be removed immediately, reducing the risk of cancer development.
  1. Longer Screening Interval:
  • Unlike FIT, colonoscopy does not need to be repeated annually. If the results are normal, the next screening may be recommended after 5 or 10 years, depending on individual risk factors.
  1. Stronger Protection Against CRC Development:
  • By directly removing precancerous lesions, colonoscopy offers stronger prevention of colorectal cancer and lowers mortality rates.

Limitations:

  1. Invasive Nature:
  • Colonoscopy is an invasive procedure, which can cause discomfort and anxiety among patients. It also carries a small risk of complications, such as bleeding or perforation.
  1. Higher Cost:
  • Colonoscopy is significantly more expensive than FIT, making it less feasible for widespread implementation in a national screening program.
  1. Resource Demands:
  • Colonoscopy requires specialized equipment, trained medical personnel, and healthcare infrastructure, which may strain resources in large-scale programs.
  1. Lower Participation Rates:
  • The invasive nature and higher cost of colonoscopy can deter some individuals from undergoing the procedure, potentially reducing overall participation rates.

Current Status in Korea

  • FIT as the Primary Screening Tool:

  • FIT remains the cornerstone of Korea’s national CRC screening program due to its affordability, simplicity, and ability to reach a large population.

  • It is particularly suited for large-scale public health initiatives in a country with universal healthcare coverage.

  • Colonoscopy as a Follow-Up Tool:

  • Individuals with positive FIT results are referred for colonoscopy to confirm the diagnosis and remove precancerous lesions.

  • Colonoscopy is also used as a first-line screening tool for individuals at higher risk of CRC, such as those with a family history of the disease or other risk factors.


Challenges and Future Directions

  1. Improving FIT Adherence:
  • Public education campaigns and reminders can help ensure consistent participation in FIT screening, enhancing its effectiveness.
  1. Enhancing Colonoscopy Quality:
  • Training healthcare professionals and ensuring high-quality colonoscopy practices will be essential for accurate diagnosis and safe therapeutic interventions.
  1. Personalized Screening Strategies:
  • Tailoring screening approaches based on individual risk profiles (e.g., age, family history, lifestyle factors) could optimize resource allocation and improve outcomes.
  1. Balancing Cost and Effectiveness:
  • Developing evidence-based policies that balance the clinical benefits of colonoscopy with its economic and resource constraints will be crucial for sustainable implementation.
  1. Continuous Evaluation:
  • Regular assessment of the screening program’s effectiveness, participation rates, and diagnostic accuracy will help refine national strategies over time.

Conclusion

In Korea, FIT and colonoscopy complement each other in the national colorectal cancer screening program. FIT serves as the primary tool for mass screening, offering simplicity and cost-effectiveness, while colonoscopy provides higher diagnostic accuracy and therapeutic benefits, making it indispensable for follow-up and high-risk populations. The optimal strategy will involve leveraging the strengths of both approaches, improving public adherence, and tailoring screening protocols to individual needs, all while ensuring economic sustainability and high-quality healthcare delivery.

Related Q&A

154

HCC - Alcohol versus other etioloiges

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can develop due to various etiologies. Alcohol-related liver disease (ALD) is a significant contributor to HCC, alongside...

155

Serum Tyrosine, HCC and mortality

Serum Tyrosine, Hepatocellular Carcinoma (HCC), and Mortality: Detailed Explanation What is Serum Tyrosine? Serum tyrosine is an aromatic amino acid (AAA) that plays a critical role in protein...

156

CEACAM6, HOXA-AS3 and miR-29a in colorectal cancer

CEACAM6, HOXA-AS3, and miR-29a are molecular components that play significant roles in colorectal cancer (CRC) progression, diagnosis, prognosis, and potential therapeutic strategies. Below is a detailed explanation of...

157

CD47 expression on survival of colorectal cancer

CD47 expression plays a significant role in determining the survival outcomes of colorectal cancer (CRC) patients. Here's a detailed explanation of its impact: What is CD47? CD47 is...

158

AFP-L3 or DCP expression is associated with poor outcomes in unresectable HCC

Yes, the expression of AFP-L3 or DCP is strongly associated with poor outcomes in patients with unresectable hepatocellular carcinoma (HCC), as demonstrated by the study you referenced. Here's...

159

MIER2 as a prognostic marker in colon adenocarcinoma

MIER2 as a Prognostic Marker in Colon Adenocarcinoma (COAD) What is MIER2? Mesoderm Induction Early Response 2 (MIER2) is a gene that has been identified to play a...

GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer